<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1282">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 01, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02267304</url>
  </required_header>
  <id_info>
    <org_study_id>C13-02</org_study_id>
    <secondary_id>2013-003487-31</secondary_id>
    <nct_id>NCT02267304</nct_id>
  </id_info>
  <brief_title>Double Blind Randomized, Monocentric, Cross-over, Placebo-controlled Study to Evaluate the Effect of Morphine and Naloxone on Motivation (MBBAnalgesic)</brief_title>
  <acronym>MBBAnalgesic</acronym>
  <official_title>Etude Comparative Monocentrique, randomisée, en Cross Over, en Double Aveugle, Contre Placebo, de l'Action de la Morphine et de la Naloxone Dans un modèle Cognitif de Gestion Des Efforts Physiques</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current study is to examine the role of the opioïd system on the cognitive
      parameters of motivation. They are embedded in a conceptual framework of motivation that
      merges decision-making and reinforcement learning theories. Every action is conceived as
      path from one state to another. The different states are associated to different values
      (positive for rewards and negative for punishments), and the different actions to different
      costs (risk, effort and delay). The tasks are designed such that the sensitivity to the
      state and action parameters can be inferred by fitting computational models.The primary
      objective is to characterize the effect of Morphine 0,05mg/kg and Naloxone 10mg on cost
      accumulation slope, assessed in an effort management task, in which participants are asked
      to squeeze a hand grip during 30 seconds at varying level of effort in order to win monetary
      payoff. Secondary objectives are to characterize the effect of Morphine 0,05mg/kg and
      Naloxone 10mg on other cognitive parameters of motivation (assessed with a motivational
      battery that includes rating, choice and learning tasks).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Anticipated">April 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Caregiver, Investigator)</study_design>
  <primary_outcome>
    <measure>Cost Accumulation Slope (AU.)</measure>
    <time_frame>15 min after first placebo injection, 15 min after morphine (respectively naloxone) injection</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary Outcome measure is the change in this parameter between the placebo condition and the morphine (respectively naloxone) condition.This parameter will be infered from the time spent in a effort period versus a rest period within trials of an effort managing task, for each subjects.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>50 mL of sodium chloride (0,9%)</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine 0,05mg/kg</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Naloxone 10mg</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man or woman, age ≥ 18 and &lt; 50

          -  Weight between 50 kg and 90 kg.

          -  No contraindication to effort

          -  No evolutive pathology that could interfere with the current study signed consent

          -  medical insurance (&quot;sécurité sociale&quot;)

        Exclusion Criteria:

          -  Age &lt; 18 or &gt; 50

          -  Smokers

          -  Person under curatorship, or guardianship, or with civil rights deprivation

          -  History of neurologic or psychiatric pathology

          -  Chronic or actual consumption of alcohol, or psychotropic drugs

          -  pregnancy, breastfeeding

          -  Woman of childbearing potential without effective contraception

          -  Liver failure

          -  Severe Cardiovascular Disorders

          -  Severe Cerebrovascular Discorders

          -  Morphine (or Naloxone) hypersensitivity/addiction

          -  Treatment contraindicated: morphine dérivatives, neuroleptics, barbiturate,
             benzodiazepine, anxiolytics, hypnotics, antidepressant, antihistamine,
             antihypertensives, beta blocker, baclofen, thalidomide

          -  Enzyme inducers, (rifampicine, …)

          -  Treatment that can interfere with the performance of the subject: beta2 adrenergic
             agonists, analgesics, corticosteroïds, anti-inflammatory drugs, …
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean -Christophe Corvol, MCU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>CIC Neurologie GH Pitié Salpêtrière</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CIC Neurologie GHPS</name>
      <address>
        <city>Paris</city>
        <zip>75013</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Christophe Corvol, MCU-PH</last_name>
      <phone>0157274658</phone>
      <email>jccorvol@icm-institute.org</email>
    </contact>
    <contact_backup>
      <last_name>Mathias Pessiglione, PhD</last_name>
      <phone>0157274324</phone>
      <email>mathias.pessiglione@gmail.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 23, 2015</lastchanged_date>
  <firstreceived_date>September 24, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>volunteers</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Naloxone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
